The drug consists of bupivacaine encapsulated in DepoFoam, the company’s technology that allows the analgesic effects to last longer. The drug is designed to provide 72 hours of post-surgical non-opioid pain relief, according to the website. The FDA expects to complete its review of Exparel by July 2011.
Read the Trading Markets report on Exparel.
Read more on anesthesia:
–Anesthesiologist Tasks Colleagues With Peri-Operative Improvement in 2011
–Blocking Receptor Might Help Control Post-Surgery Pain and Inflammation
–10 Anesthesia Studies Making Recent Headlines
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.